Effect of long term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women A randomized trial
Long-term intranasal oxytocin and placebo administration improve sexual function and symptoms of depression in women over time with no treatment, sequence (placebo first/second), or interaction effect.
Dana A. Muin, M.D., M.Sc., Michael Wolzt, M.D., Ph.D., Rodrig Marculescu, M.D., Ph.D., Safoura Sheikh Rezaei, M.D., Mohamed Salama, M.D., Ph.D., Carola Fuchs, Anton Luger, M.D., Ph.D., Elia Bragagna, M.D., Brigitte Litschauer, M.D., Ph.D., Michaela Bayerle-Eder, M.D., Ph.D.
Volume 104, Issue 3, Pages 715-723
To assess the effect of on-demand intranasal oxytocin administration on female sexual function and activity.
Randomized, prospective, double-blind, placebo-controlled, crossover trial with duration of 22 weeks.
Academic medical center.
Thirty pre-and postmenopausal women with sexual dysfunction.
Over 8 weeks, intranasal oxytocin (32 IU) or placebo self-administered by women within 50 minutes before sexual intercourse; after a washout period of 2 weeks, crossover with patients switched to the alternate group for another 8 weeks.
Main Outcome Measure(s):
Primary outcome parameter: Female Sexual Function Index (FSFI); secondary outcome parameters: Female Sexual Distress Scale (FSDS), Sexual Quality of Life–Female (SQOL-F), Sexual Interest and Desire Inventory–Female (SIDI-F), and Hamilton depression scale (HDS).
After oxytocin and placebo, the FSFI score increased by 26% and 31%, SQOL-F score by 144% and 125%, and SIDI-F score by 29% and 23%, respectively (repeated measures analysis of variance between groups). After oxytocin and placebo, the FSDS score decreased by 36% and 45%, respectively (repeated measures analysis of variance between groups). There was no statistically significant treatment, sequence (placebo first/second), or interaction effect.
Long-term intranasal oxytocin and placebo administration both improved sexual function and symptoms of depression in women over time with no treatment, sequence (placebo first/second), or interaction effect.
Clinical Trial Registration Number: